IL18 and acute respiratory distress syndrome: The results of the present study showed that the therapeutic effect of pMSCs in ALI therapy may be due to their unique immunoregulatory properties, including anti‐inflammatory cytokine (IL‐10) secretion and inhibition of proinflammatory cytokine (TNF-α, IL-1β and IL-18) expression, which is in agreement with previous findings (7).